OBJECTIVE:To collect data and investigate the effects of Huangkui capsule(黄葵胶囊,HKC)on chronic kidney disease(CKD).METHODS:PubM ed,Embase,Cochrane Library,and three Chinese databases(China National Knowledge Infras...OBJECTIVE:To collect data and investigate the effects of Huangkui capsule(黄葵胶囊,HKC)on chronic kidney disease(CKD).METHODS:PubM ed,Embase,Cochrane Library,and three Chinese databases(China National Knowledge Infrastructure,Wanfang,and China Science and Technology Journal Database)were searched for articles published until October 2020.Randomized controlled trials(RCTs)of HKCs used for treating CKD were reviewed.Data were organized and analyzed using RevMan 5.3 software.RESULTS:HKC significantly lowered the blood urea nitrogen(BUN)level[mean difference(MD)=-2.26;95%confidence interval(CI),-2.91 to-1.61],serum creatinine level(MD=-17.45;95%CI,-22.29 to-12.60),and 24-h urine protein content(MD=-0.73;95%CI,-1.00 to-0.46)and improved the glomerular filtration rate(GFR)(MD=10.69;95%CI,5.57 to 15.81)and serum albumin level(MD=2.20;95%CI,0.49 to 3.90).CONCLUSIONS:Our findings show that HKC could lower the BUN level,serum creatinine level,and 24-h urine protein content.HKC also improved GFR and serum albumin levels.However,high-quality RCTs in other countries with larger sample sizes are warranted to confirm these findings.展开更多
目的 探究黄葵胶囊联合达格列净对早期糖尿病肾病患者胱抑素C(Cys-C)、α1-微球蛋白(α1-MG)的影响。方法 115例早期糖尿病肾病患者,依据随机数字表法将其分为达格列净组(35例)、黄葵胶囊组(38例)、联合组(42例)。达格列净组给予达格列...目的 探究黄葵胶囊联合达格列净对早期糖尿病肾病患者胱抑素C(Cys-C)、α1-微球蛋白(α1-MG)的影响。方法 115例早期糖尿病肾病患者,依据随机数字表法将其分为达格列净组(35例)、黄葵胶囊组(38例)、联合组(42例)。达格列净组给予达格列净治疗,黄葵胶囊组给予黄葵胶囊治疗,联合组给予黄葵胶囊联合达格列净治疗。对比三组治疗前后血糖[空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、炎性因子[可溶性细胞间黏附分子1(sICAM-1)、高迁移率族蛋白B1(HMGB1)、单核细胞趋化蛋白1(MCP-1)]、胱抑素C(Cys-C)、α1-微球蛋白(α1-MG)水平。结果 治疗后,达格列净组FBG为(6.79±0.96)mmol/L、2 h PG为(10.12±2.07)mmol/L、HbA1c为(7.03±1.02)%;黄葵胶囊组FBG为(6.64±0.91)mmol/L、2 h PG为(9.34±1.96)mmol/L、HbA1c为(6.71±0.94)%;联合组FBG为(5.60±0.76)mmol/L、2 h PG为(5.65±1.13)mmol/L、HbA1c为(6.03±0.62)%。治疗后,三组FBG、2 h PG、HbA1c水平均低于本组治疗前,且联合组FBG、2 h PG、HbA1c水平均低于达格列净组与黄葵胶囊组,差异均有统计学意义(P<0.05)。治疗后,达格列净组s ICAM-1为(168.94±24.74)μg/L、HMGB1为(10.39±1.95)μg/L、MCP-1为(155.49±14.50)ng/L;黄葵胶囊组s ICAM-1为(153.28±23.11)μg/L、HMGB1为(9.41±1.84)μg/L、MCP-1为(146.23±13.73)ng/L;联合组sICAM-1为(102.38±22.74)μg/L、HMGB1为(5.20±1.25)μg/L、MCP-1为(132.87±15.75)ng/L。治疗后,三组sICAM-1、HMGB1、MCP-1水平均低于本组治疗前,且联合组s ICAM-1、HMGB1、MCP-1水平均低于达格列净组与黄葵胶囊组,差异均有统计学意义(P<0.05)。治疗后,达格列净组Cys-C为(2.03±0.48)mg/L、尿α1-MG为(13.45±2.16)mg/L;黄葵胶囊组Cys-C为(1.92±0.51)mg/L、尿α1-MG为(12.67±2.01)mg/L;联合组Cys-C为(1.06±0.35)mg/L、尿α1-MG为(8.42±1.73)mg/L。治疗后,三组Cys-C、尿α1-MG水平均低于本组治疗前,且联合组Cys-C、尿α1-MG水平均低于达格列净组与黄葵胶囊组,差异均有统计学意义(P<0.05)。结论 黄葵胶囊联合达格列净治疗早期糖尿病肾病患者疗效显著,血糖水平逐渐降低、恢复,机体炎症情况减轻,肾功能得到有效保护,值得临床推广应用。展开更多
目的分析黄葵胶囊联合利拉鲁肽治疗早期糖尿病肾病患者的临床应用价值。方法68例早期糖尿病肾病患者,根据随机分配法分为观察组和对照组,每组34例。对照组患者实施黄葵胶囊联合胰岛素治疗,观察组实施黄葵胶囊联合利拉鲁肽治疗。比较两...目的分析黄葵胶囊联合利拉鲁肽治疗早期糖尿病肾病患者的临床应用价值。方法68例早期糖尿病肾病患者,根据随机分配法分为观察组和对照组,每组34例。对照组患者实施黄葵胶囊联合胰岛素治疗,观察组实施黄葵胶囊联合利拉鲁肽治疗。比较两组患者治疗前后的血糖控制情况[空腹血糖(FBG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PG)]及肾功能指标[尿白蛋白排泄率(UAER)以及尿微量白蛋白/肌酐比值(UACR)]。结果治疗后,两组FBG、HbA1c、2 h PG水平均低于本组治疗前,且观察组FBG、HbA1c、2 h PG水平分别为(6.31±1.13)mmol/L、(5.42±1.36)%、(8.93±2.18)mmol/L,低于对照组的(8.04±1.16)mmol/L、(7.52±0.89)%、(10.87±2.41)mmol/L,差异有统计学意义(P<0.05)。治疗后,观察组UAER、UACR水平分别为(57.26±15.33)μg/min、(64.52±13.16)mg/g,均低于对照组的(68.74±15.12)μg/min、(77.68±14.34)mg/g,差异有统计学意义(P<0.05)。结论临床上针对早期糖尿病肾病患者应用黄葵胶囊联合利拉鲁肽治疗效果显著,能够改善患者肾功能指标,有效控制患者血糖。展开更多
基金Supported by the National Natural Science Foundation of China:Study on the mechanism of Yishen Qingli Huoxue formula regulating autophagy in kidney injury caused by metabolic disorder(No.81774245)the Protective Effect of Abelmoschus Manihot via Regulating NLRP3 Inflammasome—Pyroptosis on Renal Tubule Cells(No.81873259)+1 种基金the Mechanism of Tanshinone IIA Regulates Txnip/TRX-NLRP3 Inflammasome to Inhibit Pyroptosis and Protect Glomerular Endothelial Cells(No.82004107)Jiangsu Province Hospital of Chinese Medicine Hospital-level Project,Molecular Mechanism of Abelmoschus Manihot Regulating Fatty Acid Oxidation in Renal Tubule Cells and Antagonizing Renal Fibrosis(No.Y20026)。
文摘OBJECTIVE:To collect data and investigate the effects of Huangkui capsule(黄葵胶囊,HKC)on chronic kidney disease(CKD).METHODS:PubM ed,Embase,Cochrane Library,and three Chinese databases(China National Knowledge Infrastructure,Wanfang,and China Science and Technology Journal Database)were searched for articles published until October 2020.Randomized controlled trials(RCTs)of HKCs used for treating CKD were reviewed.Data were organized and analyzed using RevMan 5.3 software.RESULTS:HKC significantly lowered the blood urea nitrogen(BUN)level[mean difference(MD)=-2.26;95%confidence interval(CI),-2.91 to-1.61],serum creatinine level(MD=-17.45;95%CI,-22.29 to-12.60),and 24-h urine protein content(MD=-0.73;95%CI,-1.00 to-0.46)and improved the glomerular filtration rate(GFR)(MD=10.69;95%CI,5.57 to 15.81)and serum albumin level(MD=2.20;95%CI,0.49 to 3.90).CONCLUSIONS:Our findings show that HKC could lower the BUN level,serum creatinine level,and 24-h urine protein content.HKC also improved GFR and serum albumin levels.However,high-quality RCTs in other countries with larger sample sizes are warranted to confirm these findings.
文摘目的 探究黄葵胶囊联合达格列净对早期糖尿病肾病患者胱抑素C(Cys-C)、α1-微球蛋白(α1-MG)的影响。方法 115例早期糖尿病肾病患者,依据随机数字表法将其分为达格列净组(35例)、黄葵胶囊组(38例)、联合组(42例)。达格列净组给予达格列净治疗,黄葵胶囊组给予黄葵胶囊治疗,联合组给予黄葵胶囊联合达格列净治疗。对比三组治疗前后血糖[空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、炎性因子[可溶性细胞间黏附分子1(sICAM-1)、高迁移率族蛋白B1(HMGB1)、单核细胞趋化蛋白1(MCP-1)]、胱抑素C(Cys-C)、α1-微球蛋白(α1-MG)水平。结果 治疗后,达格列净组FBG为(6.79±0.96)mmol/L、2 h PG为(10.12±2.07)mmol/L、HbA1c为(7.03±1.02)%;黄葵胶囊组FBG为(6.64±0.91)mmol/L、2 h PG为(9.34±1.96)mmol/L、HbA1c为(6.71±0.94)%;联合组FBG为(5.60±0.76)mmol/L、2 h PG为(5.65±1.13)mmol/L、HbA1c为(6.03±0.62)%。治疗后,三组FBG、2 h PG、HbA1c水平均低于本组治疗前,且联合组FBG、2 h PG、HbA1c水平均低于达格列净组与黄葵胶囊组,差异均有统计学意义(P<0.05)。治疗后,达格列净组s ICAM-1为(168.94±24.74)μg/L、HMGB1为(10.39±1.95)μg/L、MCP-1为(155.49±14.50)ng/L;黄葵胶囊组s ICAM-1为(153.28±23.11)μg/L、HMGB1为(9.41±1.84)μg/L、MCP-1为(146.23±13.73)ng/L;联合组sICAM-1为(102.38±22.74)μg/L、HMGB1为(5.20±1.25)μg/L、MCP-1为(132.87±15.75)ng/L。治疗后,三组sICAM-1、HMGB1、MCP-1水平均低于本组治疗前,且联合组s ICAM-1、HMGB1、MCP-1水平均低于达格列净组与黄葵胶囊组,差异均有统计学意义(P<0.05)。治疗后,达格列净组Cys-C为(2.03±0.48)mg/L、尿α1-MG为(13.45±2.16)mg/L;黄葵胶囊组Cys-C为(1.92±0.51)mg/L、尿α1-MG为(12.67±2.01)mg/L;联合组Cys-C为(1.06±0.35)mg/L、尿α1-MG为(8.42±1.73)mg/L。治疗后,三组Cys-C、尿α1-MG水平均低于本组治疗前,且联合组Cys-C、尿α1-MG水平均低于达格列净组与黄葵胶囊组,差异均有统计学意义(P<0.05)。结论 黄葵胶囊联合达格列净治疗早期糖尿病肾病患者疗效显著,血糖水平逐渐降低、恢复,机体炎症情况减轻,肾功能得到有效保护,值得临床推广应用。
文摘目的分析黄葵胶囊联合利拉鲁肽治疗早期糖尿病肾病患者的临床应用价值。方法68例早期糖尿病肾病患者,根据随机分配法分为观察组和对照组,每组34例。对照组患者实施黄葵胶囊联合胰岛素治疗,观察组实施黄葵胶囊联合利拉鲁肽治疗。比较两组患者治疗前后的血糖控制情况[空腹血糖(FBG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PG)]及肾功能指标[尿白蛋白排泄率(UAER)以及尿微量白蛋白/肌酐比值(UACR)]。结果治疗后,两组FBG、HbA1c、2 h PG水平均低于本组治疗前,且观察组FBG、HbA1c、2 h PG水平分别为(6.31±1.13)mmol/L、(5.42±1.36)%、(8.93±2.18)mmol/L,低于对照组的(8.04±1.16)mmol/L、(7.52±0.89)%、(10.87±2.41)mmol/L,差异有统计学意义(P<0.05)。治疗后,观察组UAER、UACR水平分别为(57.26±15.33)μg/min、(64.52±13.16)mg/g,均低于对照组的(68.74±15.12)μg/min、(77.68±14.34)mg/g,差异有统计学意义(P<0.05)。结论临床上针对早期糖尿病肾病患者应用黄葵胶囊联合利拉鲁肽治疗效果显著,能够改善患者肾功能指标,有效控制患者血糖。
